Trial Profile
An Observer- and Subject-Blinded, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary)
- Indications Herpesvirus infections; HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 04 Jan 2013 New source identified and integrated (ClinicalTrials.gov record NCT01756131).
- 31 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT01756131)
- 31 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT01756131)